Literature DB >> 10554538

[Effect of preventive selenium administration on development of ERCP-induced acute pancreatitis].

S Wollschläger1, K Pätzold, T Bulang, D Meissner, H Porst.   

Abstract

BACKGROUND: Sodium selenite may play a role in reduction of enhanced oxygen free radicals in the early phase of experimental acute pancreatitis. The aim of the study was to determine whether ERCP induced pancreatitis can be used as a human model for early acute pancreatitis and if a prophylactic antioxidant therapy with sodium selenite or a prophylactic antibiotic therapy has a beneficial effect on the clinical outcome in patients with ERCP. PATIENTS AND METHODS: Sixty patients were randomly allocated in 3 groups: A (n = 20, sodium selenite i.v. 1 day before ERCP 1 mg bolus/2 x 1 mg infusion); B (n = 20, metronidazole 0.5 g/ofloxacin 0.2 g before and 6 hours after ERCP); C (n = 20, controls, no prophylaxis). Various labor parameters and physical complaints after ERCP were determined.
RESULTS: Patients with an antibiotic prophylaxis or with a sodium selenite substitution had no less physical complaints or pancreatitis than the controls. Seven patients (= 11.7%) developed a pancreatitis after ERCP. Concentration of zinc, copper, manganese, vitamin A and E did not differ significantly between the various groups.
CONCLUSION: A prophylactic substitution with sodium selenite or prophylactic antibiotic therapy with metronidazole/ofloxacin has no beneficial effect on the clinical outcome in patients with ERCP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554538     DOI: 10.1007/BF03042200

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  10 in total

Review 1.  Diagnosis and prevention of post-ERCP pancreatitis.

Authors:  A Tittobello
Journal:  Endoscopy       Date:  1997-05       Impact factor: 10.093

2.  Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.

Authors:  G Cavallini; A Tittobello; L Frulloni; E Masci; A Mariana; V Di Francesco
Journal:  N Engl J Med       Date:  1996-09-26       Impact factor: 91.245

3.  Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis.

Authors:  H Messmann; W Vogt; A Holstege; G Lock; A Heinisch; A von Fürstenberg; H G Leser; H Zirngibl; J Schölmerich
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

4.  [Effect of selenium administration on various laboratory parameters in patients with acute pancreatitis].

Authors:  S Wollschläger; K Ludwig; D Meissner; H Porst
Journal:  Med Klin (Munich)       Date:  1997-09-15

5.  The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP.

Authors:  D Arvanitidis; J Hatzipanayiotis; G Koutsounopoulos; E Frangou
Journal:  Hepatogastroenterology       Date:  1998 Jan-Feb

6.  Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study.

Authors:  J M Bordas; V Toledo-Pimentel; J Llach; M Elena; F Mondelo; A Ginès; J Terés
Journal:  Gastrointest Endosc       Date:  1998-03       Impact factor: 9.427

7.  Involvement of oxygen-derived free radicals in L-arginine-induced acute pancreatitis.

Authors:  L Czakó; T Takács; I S Varga; L Tiszlavicz; D Q Hai; P Hegyi; B Matkovics; J Lonovics
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

8.  Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitonin in early phase of post-ERCP pancreatitis.

Authors:  M Oezcueruemez-Porsch; D Kunz; P D Hardt; T Fadgyas; O Kress; H U Schulz; H Schnell-Kretschmer; H Temme; S Westphal; C Luley; H U Kloer
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

9.  [Decreasing mortality in acute pancreatitis with sodium selenite. Clinical results of 4 years antioxidant therapy].

Authors:  B Kuklinski; T Zimmermann; R Schweder
Journal:  Med Klin (Munich)       Date:  1995-01-15

10.  Oxidative stress: an important phenomenon with pathogenetic significance in the progression of acute pancreatitis.

Authors:  K Tsai; S S Wang; T S Chen; C W Kong; F Y Chang; S D Lee; F J Lu
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

  10 in total
  6 in total

Review 1.  Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: What does evidence suggest?

Authors:  Clotilde Fuentes-Orozco; Carlos Dávalos-Cobián; Jesús García-Correa; Gabriela Ambriz-González; Michel Dassaejv Macías-Amezcua; Jesús García-Rentería; Jorge Rendón-Félix; Mariana Chávez-Tostado; Lizbeth Araceli Cuesta-Márquez; Andrea Socorro Alvarez-Villaseñor; Ana Olivia Cortés-Flores; Alejandro González-Ojeda
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

Review 2.  Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography.

Authors:  John G Lieb; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

3.  The importance of interleukin 18, glutathione peroxidase, and selenium concentration changes in acute pancreatitis.

Authors:  Urszula Wereszczynska-Siemiatkowska; Barbara Mroczko; Andrzej Siemiatkowski; Maciej Szmitkowski; Maria Borawska; Juliusz Kosel
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

Review 4.  Prevention of post-ERCP pancreatitis.

Authors:  Lin-Lee Wong; Her-Hsin Tsai
Journal:  World J Gastrointest Pathophysiol       Date:  2014-02-15

5.  Antioxidant supplementation for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials.

Authors:  Wan-Jie Gu; Chun-Yin Wei; Rui-Xing Yin
Journal:  Nutr J       Date:  2013-02-11       Impact factor: 3.271

6.  Influence of daily oral prophylactic selenium treatment on the dibutyltin dichloride (DBTC)-induced pancreatitis in rats.

Authors:  J Merkord; N Görl; M Lemke; A Berg; H Weber; R Ramer; G Hennighausen
Journal:  EXCLI J       Date:  2017-02-16       Impact factor: 4.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.